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ABSTRACT
Effective therapies exist for the treatment of both vaginal trichomoniasis and bacterial vaginosis
(BV). Recurrent trichomonas infection is uncommon, and significant metronidazole resistance
remains rare. The management of metronidazole-resistant trichomoniasis is dependent on suscepti-
bility studies, which can be used to guide higher doses of metronidazole therapy. Recurrent BV is
common.A mechanism for reestablishing the normal vaginal flora with H202-producing lactobacilli
remains elusive. The management of this recurrent infection is based upon a longer duration of
therapy with currently available antibiotic regimens and documentation of a clinical response using
composite clinical criteria and Gram’s stain of the vaginal secretions. (C) 1995 Wiley-Liss, Inc.
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aginitis is one of the most common problems in
clinical medicine, accounting for more than 10
million office visits each year. It is the most com-
mon reason for a patient to visit her obstetrician-
gynecologist. Bacterial vaginosis (BV) and vaginal
trichomoniasis are 2 of the most common causes of
infective vaginitis. While effective therapy for these
diseases exists, recurrent disease is not uncommon.
Crucial management strategies for patients with
recurrent disease include confirmation of the diag-
nosis and clinical monitoring of the disorder while
the patient undergoes antimicrobial therapy.
RECURRENT TRICHOMONIASIS
Trichomonas vaginalis is one of the most common
organisms causing vaginitis in women worldwide
and affects approximately 3 million American
women annually.
2 Metronidazole remains the drug
of choice for the treatment of trichomonas vagini-
tis. The most extensively studied metronidazole reg-
imens have been 200-250 mg t.i.d, for 7 days and
a single 2-g dose; these regimens have median cure
rates of 92% and 96%, respectively.
3 Treatment
failures have been attributed to noncompliance with
therapy, reinfection, or in situ inactivation or mal-
absorption of the drug.
4-6 Although metronidazole
7 resistance is increasing, it is still uncommon.
The 2-g single-dose regimen minimizes non-
compliance and is more practical for the treatment
ofsexual partners. Sexual partners should be treated
since reinfection rates of 6.2% to 23.7% are noted
in women whose sexual partners are not treated
simultaneously.
6-8 In addition, T. vaginalis can be
a cause of tetracycline-resistant nongonococcal ure-
thritis in males.
Recommended Regimens
Metronidazole is the only trichomonacidal drug
available in the United States. Metronidazole, 2 g
orally in a single dose, is the current recommended
regimen for the treatment of both men and women
with trichomoniasis.
9 An alternative regimen is
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TABLE I. Treatment of metronidazole-resistant trichomoniasis
Resistance Aerobic MLC Metronidazole
level (lg/ml) regimen
Marginal 50
Low < 100
Moderate 100-200
High >200
High (alternate)
Retreatment with standard dose
2 g qd for 3-5 days
2-2.5 g qd for 7-10 days
3-3.5 g qd for 14-18 days
2 g IV q 6-8 h for 3 days
aModified from references 3, 5, and I.
bConcomitant vaginal treatment may be helpful.
metronidazole, 500 mg orally b.i.d, for 7 days. If
failure occurs with either regimen, the patient
should be retreated with one of these standard regi-
mens. Eighty-five percent of initial treatment fail-
ures will respond to a repeat single 2-g dose of
metronidazole.
10 If repeated failure occurs, the pa-
tient should be treated with a 2-g dose of metro-
nidazole daily for 3-5 days. Compliance issues and
the possibility of reinfection should be addressed.
Cases of additional culture-documented treatment
failure should be managed in consultation with an
expert. The evaluation of such cases should include
a determination of the susceptibility of T. vaginalis
to metronidazole.
Metronidazole Resistance
In 1979, reports concerning the emergence of met-
ronidazole-resistant strains of T. vaginalis were pub-
lished.
11-13 Similar cases became clinically evident
in the United States and prompted the Centers for
Disease Control (CDC) to evaluate the susceptibil-
ity to metronidazole of isolates from women failing
at ]east 2 standard treatment regimens with metro-
nidazole and in whom reinfection was unlikely be-
cause of the interim absence of coitus.
14 Although
methods for determining the sensitivity of T. vagi-
nalis are not standardized, the testing procedures
identify 4 levels of metronidazole resistance: mar-
ginal, low, moderate, and high (Table 1). Aerobic
values for the mean lethal concentration (MLC), or
trichomonacidal level of metronidazole, appear to
correlate better with the clinical response to therapy
than the results of susceptibility testing done under
anaerobic conditions. Although there is consider-
able overlap in the MLC values of isolates from
responsive and unresponsive infections, an aerobic
MLC value of >100 g/ml is highly associated
with clinical resistance.
15
Patients with marginally resistant organisms re-
spond well to repeat treatment with standard doses.
Increased resistance requires larger doses of metro-
nidazole administered for longer periods (Table 1).
As noted above, patients with repeated treatment
failure should have cultures of their vaginal secre-
tions and the T. vaginalis isolate tested for its sus-
ceptibility. This technique involves suspending a
swab of the vaginal secretions in modified Dia-
mond’s medium followed by incubation at 35-37C
for >24 h. This culture medium should be pre-
warmed prior to inoculating the vaginal sample.
Once a positive culture is confirmed by a wet prep-
aration of the original culture, a second prewarmed
culture tube should be inoculated and mailed by
overnight delivery service to a reference laboratory
capable of performing susceptibility testing. The
patient may be placed on intravaginal clotrimazole
in an attempt to ameliorate her symptoms while
awaiting the results of the T. vaginalis susceptibil-
ity testing.
Once the level of resistance is known, appropri-
ate doses of metronidazole should be prescribed
(Table 1). Concurrent treatment with vaginal met-
ronidazole has been recommended for patients with
isolates showing a high level of resistance. Prior to
the availability of 0.75% metronidazole vaginal
gel, 500-mg tablets of metronidazole (not enteric
coated) were used as vaginal suppositories.
4 Now,
5 g of gel (37.5 mg of metronidazole) may be used
intravaginally b.i.d, as an adjunct to high-dose oral
therapy in highly resistant cases.
Patients with significant resistance should be
evaluated for parasite persistence with a wet prepa-
ration of the vaginal secretions prior to discontinu-
ing metronidazole therapy. If motile trichomonads
are noted, continued therapy is indicated or consid-
eration of higher doses of metronidazole. Once the
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parasite disappears from the wet preparation, a cul-
ture should be performed to ensure that low levels
of trichomonads do not remain. A follow-up ap-
pointment 6 weeks after therapy has been com-
pleted is also recommended. A repeat evaluation of
the vaginal secretions and trichomonas culture
should be performed at this time.
Oral absorption of metronidazole is almost com-
plete. The drug is metabolized in the liver, and the
hydroxy metabolite may act synergistically with the
parent compound. Nausea and vomiting develop
less frequently during IV than oral therapy at nor-
mal-to-moderate doses. However, high doses may
lead to gastrointestinal side effects regardless of the
route of administration and may be due to the accu-
mulation of the hydroxy metabolite. For this rea-
son, hospitalization for the parenteral use of met-
ronidazole for the treatment of resistant trichomonas
vaginitis is usually not recommended. Other man-
ifestations of metronidazole toxicity include metal-
lic taste, glossitis, stomatitis, urticaria, vertigo, con-
vulsive seizures, and peripheral neuropathy.
Neurotoxicity appears to be a consistent problem
when high-dose treatment exceeds 3 or 4 days.
7
A number of similar nitroimidazole derivatives,
such as tinidazole and ornidazole, are available in
countries worldwide including Canada and the Ba-
hamas, but not the United States. Although cross
resistance is common, it is often incomplete. These
alternative agents can be considered if susceptibility
studies suggest that certain metronidazole-resistant
infections can be effectively treated with these anti-
microbials.
Several investigators have reported the use of
agents in addition to or other than metronidazole in
the treatment of resistant trichomonal infections.
Grossman and Galask
4 added a twice weekly 3%
acetic acid vaginal wash to their metronidazole reg-
imen in successfully treating 2 patients with met-
ronidazole-resistant trichomoniasis. In a different
case, a providone-iodine douche, 20 ml of a 10%
solution, given b.i.d, for 4 days (8 douches) and
repeated 2 weeks later for 2 days (4 douches) was
successful in eradicating a metronidazole-resistant
trichomonal infection that had previously been un-
responsive to high-dose metronidazole and ornida-
zole.
16 Livengood and Lossick17 reported that the
routine use of a contraceptive suppository contain-
ing 100 mg of nonoxynol-9 resulted in complete
resolution of vaginal irritative symptoms after the
second episode of protected coitus. Further fol-
low-up with wet preparations and culture docu-
mented resolution of the resistant trichomonas
vaginitis. The prior use of gentian violet, ni-
trofurantoin, chlorhexidine, clotrimazole, povi-
done-iodine, 3% acetic acid, and hydrogen perox-
ide had been unsuccessful. Oral mebandazole with
and without adjunctive vaginal mebendazole, al-
though showing some in vitro activity against T.
vaginalis, failed to eradicate the parasite in 2 women
with resistant infection.
18 Lactobacillus immuno-
therapy using a vaccine of a lyophilisate of inacti-
vated microorganisms of selected strains of Lacto-
bacillus acidophilus, originally isolated from vaginal
secretionsofpatientswith trichomoniasis, was unsuc-
cessfully used in conjunction with high-dose met-
ronidazole in an attempt to eradicate a metro-
nidazole-resistant trichomonal infection.
19
RECURRENT BV
BV is considered the most common vaginal infec-
tion in women. It is a complex alteration of the
normal vaginal flora resulting in the replacement
of a predominantly HzOz-producing lactobacilli
melieu with a mixed flora of anaerobic bacteria,
Gardnerella vaginalis, and Mycoplasma hominis.
Common symptoms associated with BV include ex-
cessive vaginal discharge and vaginal malodor, al-
though almost half of the women with this disorder
are asymptomatic.
2 BV is associated with a num-
ber of infectious reproductive sequelae including
upper genital tract infection, adverse pregnancy
outcomes, and postoperative infection,z Of sev-
eral antibiotics that have been studied, including
sulfa vaginal creams, ampicillin, doxycycline, clin-
damycin, and metronidazole, the latter 2 appear to
be the most effective. Clindamycin and metronida-
zole can be administered either orally or intravagi-
nally for the treatment ofBV.
21-27 These agents are
associated with cure rates around 80% 4 weeks
following treatment.
Long-term recurrence rates are observed in pa-
tients with BV irrespective of" the treatment method.
Sobel et al.
28 noted that over half of cured patients
developed symptomatic clinical and laboratory
mainfestations of BV within 3 months of complet-
ing therapy. Up to 80% of women developed re-
current BV within 9 months of therapy in a Seattle
study.
29 The reasons for recurrence are not under-
stood. One explanation suggests reinfection, either
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endogenously or by a male partner who is colonized
with BV-associated microorganisms. Data indicat-
ing that the treatment of male sexual partners fails
to reduce the incidence of recurrent BV argue
against this latter theory.
3 Other causes for recur-
rence may be explained by the persistence of BV-
associated microorganisms. This persistence may
occur when the microorganisms are inhibited but
not killed, and pathogenic bacteria gain predomi-
nance because the normal, protective lactobacillus-
dominant flora has not been reestablished. 29’3
31 Cook et al., in a study of 31 women with
recurrent BV, noted that relapse appeared to reflect
a failure of the complete normalization of the vagi-
nal ecosystem without indicating resistance to metro-
nidazole. Although the therapeutic implications of
their observations remain conjectural, more pro-
longed antimicrobial therapy could conceivably re-
sult in a lower recurrence rate because of a dimin-
ished anaerobic flora. Because failure to reestablish
a normal profile of lower-genital-tract flora is en-
countered, even among women considered clini-
cally cured of BV, the restoration of a lactobacilli-
dominant vaginal flora should be a central object of
therapy. Intravaginal inoculation of Lactobacillus
preparations could potentially improve outcome in
these patients. Unfortunately, over-the-counter
Lactobacillus preparations adhere poorly to vaginal
epithelial cells, making vaginal colonization un-
likely.
2 In addition, most commercially available
Lactobaci]]us preparations do not contain the EgOe-
producing strains known to be protective in the
vagina. Despite these observations, a diet associ-
ated with daily yogurt consumption has recently
been shown to decrease the risk for recurrent vul-
vovaginal candidiasis.
4 Since the postulated mech-
anism of action concerns colonization resistance by
lactobacilli of potential pathogens, a similar study
should be performed with respect to women with
recurrent BV.
MANAGEMENT OF RECURRENT BV
The clinical approach to the management ofwomen
with symptomatic recurrent BV should first con-
cern confirming the diagnosis. Composite clinical
criteria (homogenous discharge, pH >4.5, clue
cells, positive whiff test) should be used initially
and confirmed by evaluating a Gram’s stain of vag-
inal secretions from the lateral vaginal sidewall.
Vulvovaginal candidiasis may be present in cases of
TABLE 2. Treatment of recurrent BV
Antimicrobial agent Dose Duration
Metronidazole 500 mg p.o.b.i.d. 14 days
Clindamycin 300 mg p.o.b.i.d. 14 days
Clindamycin 2% vaginal cream qd 14 days
Metronidazole 0.75% vaginal gel b.i.d. 14 days
Amoxicillin/clavulanate 500 mg p.o.t.i.d. 14 days
Metronidazole 2 g p.o. q month 6 months
aMinimum duration of therapy. Discontinuation of antibiotic therapy is
based upon normalization of the vaginal secretions as documented by
microscopy of a wet preparation and Gram’s stain.
bprophylactic regimen.
recurrent BV and, if present, should be treated
prior to or concurrently with the institution of ther-
apy for BV.
3s
Once the diagnosis of BV is confirmed, treat-
ment with an oral regimen of metronidazole or
clindamycin should then be undertaken (Table 2).
Although topical therapy is equally effective, it is
crucial to be able to evaluate the vaginal secretions
in women with recurrent or persistent symptoms to
ensure that microscopy of a wet preparation con-
firms the normalization ofthe vaginal flora. Topi-
cal medications interfere with performing a wet
preparation of the vaginal secretions; therefore, the
oral route of administration is preferred. Therapy
should be continued until an absence of clue cells is
documented by microscopy and confirmed by a
Gram’s stain of vaginal secretions from the lateral
vaginal sidewall. If, after 2 weeks of therapy, clue
cells persist, a change to an alternative antibiotic is
suggested. If both clindamycin and metronidazole
are ineffective, this author has used amoxicillin/
clavulanate with good results. Once the patient is
rendered asymptomatic and a follow-up evaluation
confirms the reestablishment of normal flora or at
least an absence of clue cells, intermittent single-
dose prophylaxis with 2 g of metronidazole once a
month can be considered. The 2-g dose of metro-
nidazole is the only regimen proved to be effective
as single-dose therapy of BV.
22
The microflora may not revert to a lactobacilli
predominance during therapy or even immediately
after therapy because of the activity of clindamycin
or amoxicillin/clavulanate against lactobacilli. It
sometimes takes several weeks for the lactobacilli
predominance to appear in women after treatment
and cure by clinical criteria.
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The sexual transmission ofBV is controversial.
36
Generally, treatment of the male sexual partner of a
woman with BV is not recommended. However,
BV-associated bacteria can be isolated from the urine
and urethral scrapings of the male partners of
women with BV. Moreover, treatment of both the
patient and her partner for a longer time results in
significantly higher cure rates.
37 For these reasons,
concurrent therapy of the male sexual partner of the
patient with recurrent BV may be considered. In
addition, condom use should be recommended un-
til such therapy is completed. Not only does con-
dom use protect the patient from the potential of a
sexually transmitted reinfection, but it also avoids
alkalinization of the vagina by the ejaculate, which
may help in reestablishing a normal vaginal pH
and therefore normal vaginal flora.
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